Exam (elaborations)

TREATMENT NR547 EXAMS LATEST UPDATE

1 view 0 purchase

Course
NR547

Institution
NR547

[Show more]

Preview 2 out of 6 pages

View example

Uploaded on October 25, 2024
Number of pages 6
Written in 2024/2025
Type Exam (elaborations)
Contains Questions & answers

treatment nr547 exams latest update pines sga se

MUTUKACOURSEHERO

Member since 6 months 9 documents sold

CA$12.72

Added

Add to cart

Add to wishlist

100% satisfaction guarantee
Immediately available after payment
Both online and in PDF
No strings attached

TREATMENT NR547 EXAMS LATEST UPDATE

Pines
SGA
Sedation is a common side effect.
Least risk of EPS.
High risk for weight gain and metabolic abnormalities.
Olanzapine (Zyprexa)
"Pine" SGA
FDA approved for treatment in those age 13 and older.
Best tolerated antipsychotic, but high metabolic risk.
Highest risk for weight gain, blood dyscrasias, QT prolongation, CVD, cerebrovascular
effects, hyperglycemia, and hyperprolactinemia.
Requires up to 30% dosage increase for patients who smoke.
Quetiapine (Seroquel)
"Pine" SGA
FDA approved for treatment in those age 13 and older.
Moderate metabolic risk.
Low EPS risk.
Risk for orthostatic hypotension, blood dyscrasias (neutropenia, leukopenia, and
agranulocytosis), QT prolongation, weight gain, and renal/hepatic impairment.
Asenapine (Saphris)
"Pine" SGA
FDA approved for age 10 and older.
Available as sublingual and patch.
Low metabolic risk.
Clozapine (Clozaril)
"Pine" SGA
Approved for treatment resistant schizophrenia and chronic suicidal behavior in
schizophrenia or schizoaffective disorder.
Not indicated for acute presentation of schizophrenia.
Low EPS risk.
ANC must be >1500 when used and requires regular monitoring of WBC, granulocyte,
and neutrophil counts.
High metabolic risk, highest risk for weight gain, black box warning: may cause severe
neutropenia. Contraindicated in liver disease/failure. Not a first choice treatment.
Clozapine monitoring schedule
Baseline ANC, CBC should be monitored weekly for 6 months, every 2 weeks for
months 6-12, then monthly thereafter. It is the only medication approved by FDA for
preventing suicide in clients with schizophrenia.
2 Dones and a Rone
SGA
Less sedating and cause less weight gain, but higher risk for hyperprolactinemia and
EPS.
Risperidone (Risperidol)

, "Done" SGA
FDA approved for age 13 and older.
Moderate metabolic risk, highest risk for hyperprolactinemia.
Risk of blood dyscrasias, QT prolongation, cardiovascular and cerebrovascular effects.
Dose not interact with CYP3A4 inhibitors or inducers, therefore, can be administered
with medications like Amiodarone.
Paliperidone (Invega)
"Done" SGA
FDA approved for ages 12 and older.
Moderate metabolic risk
Ziprasidone (Geodon)
"Done" SGA
FDA approved for age 10 and older.
IM dosing in acute agitation associated with schizophrenia.
Low metabolic risk, lowest risk for weight gain.
Contraindicated with QT, recent MI, or uncompensated HF.
High incidence of rash/urticaria r/t Stevens-Johnson syndrome and drug reaction with
eosinophilia and systemic syndrome (DRESS).
Iloperidone (Fanapt)
"Done" SGA
Moderate risk for weight gain, low risk for hyperlipidemia.
Lurasidone (Latuda)
"Done" SGA
FDA approved for age 13 and older.
Should be taken with food, at least 350 calories for maximum absorption.
Low metabolic risk.
2 Pips and a Rip
Low risk for metabolic side effects and weight gain.
Potential for EPS.
Aripiprazole, Brexpiprazole, Cariprazine
Aripiprazole (Abilify)
"Pip" SGA
Low metabolic risk, weight gain, and orthostatic hypotension.
Brexpiprazole (Rexulti)
"Pip" SGA
Considered pro-cognitive.
Low metabolic risk.
Cariprazine (Vraylar)
"Rip" SGA
Low metabolic risk.
First generation antipsychotics
Effective for positive symptoms but higher incidence of unwanted side effects, such as
dystonia, parkinsonism, akathisia, and TD, which increase with long term use. FGA are
generally not first choice but may be selected in hospitalization in clients with psychosis
needing quick treatment for positive symptoms. Others may need an FGA due to failed
treatment with SGA, symptom severity, or availability of long-acting injectable.

The benefits of buying summaries with Stuvia:

Guaranteed quality through customer reviews

Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.

Quick and easy check-out

You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.

Focus on what matters

Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!

Frequently asked questions

What do I get when I buy this document?

You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.

Satisfaction guarantee: how does it work?

Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.

Who am I buying these notes from?

Stuvia is a marketplace, so you are not buying this document from us, but from seller MUTUKACOURSEHERO. Stuvia facilitates payment to the seller.

Will I be stuck with a subscription?

No, you only buy these notes for CA$12.72. You're not tied to anything after your purchase.

Can Stuvia be trusted?

4.6 stars on Google & Trustpilot (+1000 reviews)

82977 documents were sold in the last 30 days

Founded in 2010, the go-to place to buy study notes for 14 years now

Start selling

Exam (elaborations)

TREATMENT NR547 EXAMS LATEST UPDATE

Document information

Subjects

Written for

Seller

Reviews received

Content preview